SBIR-STTR Award

  1. You are here:    Home
  2. Search Databases
  3. Search SBIR-STTR Awards
  4. SBIR-STTR Award

Sustained Release Naltrexone as Treatment for Alcoholism
Award last edited on: 1/30/14

Sponsored Program
SBIR
Awarding Agency
NIH : NIAAA
Total Award Amount
$849,193
Award Phase
2
Solicitation Topic Code
-----
Principal Investigator
Raymond Bartus

Company Information

Alkermes PLC (AKA: Alkermes Inc~Alkermes Controlled Therapeutics Inc)

852 Winter Street
Waltham, MA 02451
   (781) 609-6000
   financial@alkermes.com
   www.alkermes.com
Location: Multiple
Congr. District: 05
County: Middlesex

Phase I

Contract Number: N43AA001002-000
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
2000
Phase I Amount
$99,193
This proposal will develop a sustained release formulation of naltrexone to be given subcutaneously. The formulation will deliver therapeutic concentrations of naltrexone for 30 days. Pharmacokinetic testing will be conducted in rats and later in primates while local irritability testing will be carried out in rabbits. Subsequently, the investigators plan to proceed rapidly into clinical trials to demonstrate safety and efficacy of the formulation with the goal of achieving regulatory approval to market the new product for the treatment of alcoholic patients

Phase II

Contract Number: N44AA011010-000
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
2001
Phase II Amount
$750,000
___(NOTE: Note: no official Abstract exists of this Phase II projects. Abstract is modified by idi from relevant Phase I data. The specific Phase II work statement and objectives may differ)___ This proposal will develop a sustained release formulation of naltrexone to be given subcutaneously. The formulation will deliver therapeutic concentrations of naltrexone for 30 days. Pharmacokinetic testing will be conducted in rats and later in primates while local irritability testing will be carried out in rabbits. Subsequently, the investigators plan to proceed rapidly into clinical trials to demonstrate safety and efficacy of the formulation with the goal of achieving regulatory approval to market the new product for the treatment of alcoholic patients